JP2009501797A5 - - Google Patents

Download PDF

Info

Publication number
JP2009501797A5
JP2009501797A5 JP2008522862A JP2008522862A JP2009501797A5 JP 2009501797 A5 JP2009501797 A5 JP 2009501797A5 JP 2008522862 A JP2008522862 A JP 2008522862A JP 2008522862 A JP2008522862 A JP 2008522862A JP 2009501797 A5 JP2009501797 A5 JP 2009501797A5
Authority
JP
Japan
Prior art keywords
use according
macrolide
formulated
administration
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008522862A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009501797A (ja
Filing date
Publication date
Priority claimed from US11/183,355 external-priority patent/US20070014760A1/en
Application filed filed Critical
Priority claimed from PCT/US2006/027713 external-priority patent/WO2007011880A2/en
Publication of JP2009501797A publication Critical patent/JP2009501797A/ja
Publication of JP2009501797A5 publication Critical patent/JP2009501797A5/ja
Pending legal-status Critical Current

Links

JP2008522862A 2005-07-18 2006-07-18 増強された眼神経保護／神経刺激 Pending JP2009501797A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/183,355 US20070014760A1 (en) 2005-07-18 2005-07-18 Enhanced recovery following ocular surgery
US11/263,737 US20070015697A1 (en) 2005-07-18 2005-11-01 Enhanced ocular neuroprotection and neurostimulation
PCT/US2006/027713 WO2007011880A2 (en) 2005-07-18 2006-07-18 Enhanced ocular neuroprotection/neurostimulation

Publications (2)

Publication Number Publication Date
JP2009501797A JP2009501797A (ja) 2009-01-22
JP2009501797A5 true JP2009501797A5 (https=) 2009-09-03

Family

ID=37661858

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008522862A Pending JP2009501797A (ja) 2005-07-18 2006-07-18 増強された眼神経保護／神経刺激

Country Status (8)

Country Link
US (4) US20070014760A1 (https=)
EP (1) EP2074994A1 (https=)
JP (1) JP2009501797A (https=)
AT (1) ATE429914T1 (https=)
BR (1) BRPI0612859A2 (https=)
DE (1) DE602006006575D1 (https=)
DK (1) DK1904056T3 (https=)
ES (1) ES2326550T3 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060085246A (ko) * 2003-09-18 2006-07-26 마커사이트, 인코포레이티드 경공막 전달
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
DK1848431T3 (en) * 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
US7592330B2 (en) * 2005-08-08 2009-09-22 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
KR20140093764A (ko) 2006-02-09 2014-07-28 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
ES2563288T3 (es) 2006-03-23 2016-03-14 Santen Pharmaceutical Co., Ltd Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular
US20070237797A1 (en) * 2006-03-28 2007-10-11 Gholam A. Peyman Neural Conduit Agent Dissemination
US20070237722A1 (en) * 2006-03-28 2007-10-11 Peyman Gholam A Neural conduit agent dissemination
US20070231360A1 (en) * 2006-03-28 2007-10-04 Minu, L.L.C. Neural conduit agent dissemination
US20070297991A1 (en) * 2006-06-23 2007-12-27 Minu, L.L.C. Neural conduit agent dissemination for smoking cessation and other applications
US10695327B2 (en) 2006-09-13 2020-06-30 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
EP2083834B1 (en) * 2006-09-13 2017-06-21 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US8088789B2 (en) 2006-09-13 2012-01-03 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
WO2009114010A1 (en) * 2008-03-11 2009-09-17 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
CN105380947A (zh) * 2008-03-11 2016-03-09 万能医药公司 大环内酯化合物及它们的使用方法
US9943401B2 (en) * 2008-04-04 2018-04-17 Eugene de Juan, Jr. Therapeutic device for pain management and vision
US20100158821A1 (en) * 2008-12-22 2010-06-24 Eastman Chemical Company Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products
US8106111B2 (en) * 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
US8591025B1 (en) 2012-09-11 2013-11-26 Nexisvision, Inc. Eye covering and refractive correction methods for LASIK and other applications
US20130066283A1 (en) * 2009-10-23 2013-03-14 Nexisvision, Inc. Corneal Denervation for Treatment of Ocular Pain
EP2490620A4 (en) 2009-10-23 2017-03-22 Forsight Labs, Llc Conformable therapeutic shield for vision and pain
IT1396607B1 (it) * 2009-11-16 2012-12-14 Hmfra Hungary Ltd Liability Company Preparazioni oftalmiche a base di bdnf (brain-derived neurotrophic factor) e loro uso.
CN103281995B (zh) 2010-10-25 2016-04-06 内希斯视觉股份有限公司 识别针对视力的眼睛覆盖物的方法和设备
US9423632B2 (en) 2012-04-20 2016-08-23 Nexisvision, Inc. Contact lenses for refractive correction
US8678584B2 (en) 2012-04-20 2014-03-25 Nexisvision, Inc. Contact lenses for refractive correction
AU2012249773A1 (en) 2011-04-28 2013-11-07 Nexisvision, Inc. Eye covering and refractive correction methods and apparatus having improved tear flow, comfort, and/or applicability
US12044905B2 (en) 2011-04-28 2024-07-23 Journey1 Inc Contact lenses for refractive correction
ITRM20110233A1 (it) * 2011-05-10 2012-11-11 Univ Calabria Azitromicina, suoi sali o solvati farmaceuticamente accettabili per l?uso come neuroprotettori.
WO2013011511A1 (en) 2011-07-18 2013-01-24 Mor Research Applications Ltd. A device for adjusting the intraocular pressure
RU2494707C2 (ru) * 2011-12-23 2013-10-10 Общество с ограниченной ответственностью "Научно-производственная компания "ФАРМАСОФТ" (ООО "НПК "ФАРМАСОФТ") Способ лечения открытоугольной глаукомы
US9465233B2 (en) 2012-04-20 2016-10-11 Nexisvision, Inc. Bimodular contact lenses
JP6370779B2 (ja) * 2012-07-27 2018-08-08 クロンズ ホールディングズ カンパニー リミテッドＣｕｒｏｎｚ Ｈｏｌｄｉｎｇｓ Ｃｏｍｐａｎｙ Ｌｉｍｉｔｅｄ 眼虚血または眼の再灌流傷害を治療または予防する医薬
JP6310072B2 (ja) 2013-06-26 2018-04-11 ネクシスビジョン， インコーポレイテッド 屈折矯正のためのコンタクトレンズ
US9341864B2 (en) 2013-11-15 2016-05-17 Nexisvision, Inc. Contact lenses having a reinforcing scaffold
WO2015116559A1 (en) 2014-01-29 2015-08-06 Nexisvision, Inc. Multifocal bimodulus contact lenses
US20210275020A1 (en) * 2016-07-18 2021-09-09 Baylor College Of Medicine Non-contact air esthesiometer
IT201700066486A1 (it) * 2017-06-15 2018-12-15 Azienda Ospedaliero Univ Policlinico S Orsola Malpighi Bologn A Siero sanguigno per uso nel trattamento di patologie neurodegenerative oftalmologiche
US20220105157A1 (en) * 2019-01-04 2022-04-07 The Regents Of The University Of California Compositions and Methods for Promoting Angiogenesis in the Eye
CN111939168B (zh) * 2019-05-16 2023-02-03 沈阳福洋医药科技有限公司 一种用于预防、缓解和/或治疗纤维化的药物、组合产品及其应用
WO2021186041A1 (en) * 2020-03-19 2021-09-23 Universität Rostock Josamycin for use in prevention and treatment of fibrosis

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US634693A (en) * 1899-02-23 1899-10-10 Carnegie Steel Company Ltd Clamp for poles or columns.
FR900520A (fr) 1943-12-13 1945-07-02 Nouveau système de trusquin
US4093709A (en) * 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4131648A (en) * 1975-01-28 1978-12-26 Alza Corporation Structured orthoester and orthocarbonate drug delivery devices
US4180646A (en) * 1975-01-28 1979-12-25 Alza Corporation Novel orthoester polymers and orthocarbonate polymers
US4079038A (en) * 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
US4304767A (en) * 1980-05-15 1981-12-08 Sri International Polymers of di- (and higher functionality) ketene acetals and polyols
KR920003601B1 (ko) * 1987-09-03 1992-05-04 유니버시티 어브 죠지아 리서취 화운데이션 인코포레이티드 점안 싸이클로스포린(cyclosporin)의 조성물
US4946931A (en) * 1989-06-14 1990-08-07 Pharmaceutical Delivery Systems, Inc. Polymers containing carboxy-ortho ester and ortho ester linkages
DK0406791T3 (da) * 1989-07-05 1995-03-27 Fujisawa Pharmaceutical Co Vandigt flydende præparat til ekstern anvendelse
US5294604A (en) * 1989-12-20 1994-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating ocular diseases by periocular administration of cyclosporine A or G
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5788687A (en) * 1994-02-01 1998-08-04 Caphco, Inc Compositions and devices for controlled release of active ingredients
US5457182A (en) * 1994-02-15 1995-10-10 Merck & Co., Inc. FK-506 cytosolic binding protein, FKBP12.6
US6179817B1 (en) * 1995-02-22 2001-01-30 Boston Scientific Corporation Hybrid coating for medical devices
US6413536B1 (en) * 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5968543A (en) * 1996-01-05 1999-10-19 Advanced Polymer Systems, Inc. Polymers with controlled physical state and bioerodibility
CN1210554A (zh) * 1996-02-09 1999-03-10 表面溶解实验室公司 水基亲水涂料组合物及由其制备的产品
ATE296114T1 (de) * 1996-02-13 2005-06-15 Searle & Co Zubereitungen, enthaltend einen cyclooxygenase-2- inhibitor und einen leukotrien-b4-rezeptor- antagonisten
US6013763A (en) * 1996-06-04 2000-01-11 Genentech, Inc. Peptide variants of protein A
CA2265743A1 (en) * 1996-09-13 1998-03-19 Advanced Medicine Research Institute Ophthalmic composition of neurotrophic factor, optic nerve functional disorder-treating agent and method for treating optic nerve functional disorder
US5952371A (en) * 1996-10-16 1999-09-14 Merck & Co., Inc. Triterpene derivatives with immunosuppressant activity
AUPO427196A0 (en) * 1996-12-19 1997-01-23 University Of Sydney, The A method for preventing or controlling cataract
US6670398B2 (en) * 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
US20030181692A1 (en) * 1997-06-06 2003-09-25 Jian Ni 207 human secreted proteins
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
US6015815A (en) * 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
JP2002509555A (ja) * 1998-04-06 2002-03-26 藤沢薬品工業株式会社 新規用途
US6218423B1 (en) * 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
US6864232B1 (en) * 1998-12-24 2005-03-08 Sucampo Ag Agent for treating visual cell function disorder
US6462071B1 (en) * 2000-03-02 2002-10-08 Vitreo-Retinal Technologies, Inc. Agents for intravitreal administration to treat or prevent disorders of the eye
US6239113B1 (en) * 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US7063857B1 (en) * 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
US6482799B1 (en) * 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
AU6526100A (en) * 1999-08-06 2001-03-05 Board Of Regents, The University Of Texas System Drug releasing biodegradable fiber implant
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6489335B2 (en) * 2000-02-18 2002-12-03 Gholam A. Peyman Treatment of ocular disease
EP1142566B1 (fr) * 2000-04-07 2003-10-01 Laboratoire Medidom S.A. Formulations ophtalmiques à base de ciclosporine, d'acide hyaluronique et du polysorbate
US6613355B2 (en) * 2000-05-11 2003-09-02 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
US6534693B2 (en) * 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
US6440942B1 (en) * 2000-12-22 2002-08-27 Enanta Pharmaceuticals, Inc. 14-membered macrolides derived from leucomycins
US6462026B1 (en) * 2001-02-16 2002-10-08 Enanta Pharmaceuticals, Inc. Bicyclic leucomycins
US6713081B2 (en) * 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
US6436906B1 (en) * 2001-04-02 2002-08-20 Enanta Pharmaceuticals, Inc. 9-amino-14-membered macrolides derived from leucomycins
US6524606B1 (en) * 2001-11-16 2003-02-25 Ap Pharma, Inc. Bioerodible polyorthoesters containing amine groups
US20040162315A1 (en) * 2002-07-23 2004-08-19 Hellberg Mark R. Use of compounds for treating conditions resulting from injury to the corneal nerve after LASIK and other ocular surgeries or trauma
US7083802B2 (en) * 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US10575605B2 (en) 2010-03-09 2020-03-03 F.D. Worldwide Merchandise Group, Inc. Jewelry stones set with prongs and invisible settings
US10328305B1 (en) 2016-06-06 2019-06-25 Joseph D Maresh Exercise machine

Similar Documents

Publication Publication Date Title
JP2009501797A5 (https=)
Yadav et al. Glaucoma: Current treatment and impact of advanced drug delivery systems
Casson Medical therapy for glaucoma: A review
Tangri et al. Basics of ocular drug delivery systems
Singh et al. Promising therapeutic drug delivery systems for glaucoma: a comprehensive review
Thakur Singh et al. Minimally invasive microneedles for ocular drug delivery
Kwon et al. Potential therapeutic usage of nanomedicine for glaucoma treatment
Schopf et al. Topical ocular drug delivery to the back of the eye by mucus-penetrating particles
Kearns et al. Drug delivery systems for the eye
Bravo-Osuna et al. Microspheres as intraocular therapeutic tools in chronic diseases of the optic nerve and retina
Goyal et al. Current nanotechnological strategies for treating glaucoma
WO2007011880A3 (en) Enhanced ocular neuroprotection/neurostimulation
JP2008540552A5 (https=)
JP2015524473A5 (https=)
CA2582374A1 (en) Ocular delivery of polymeric delivery formulations
Moosa et al. A review of topically administered mini-tablets for drug delivery to the anterior segment of the eye
WO2008045330A3 (en) Effective delivery of cross-species a3 adenosine-receptor antagonists to reduce intraocular pressure
Mandal et al. Developments in emerging topical drug delivery systems for ocular disorders
JP6727623B2 (ja) 角結膜被覆シート作製用キット及び角結膜被覆シートの作製方法
Yang et al. Progress in the Application of Microneedles in Eye Disorders and the Proposal of the Upgraded Microneedle with Spinule: Yang et al.
Villanueva et al. Turning the screw even further to increase microparticle retention and ocular bioavailability of associated drugs: The bioadhesion goal
Kaith et al. Pullulan as a sustained release carrier for ocular drug delivery: a review
WEINER Drug delivery systems in ophthalmic applications
Hajare et al. A rational approach to ocular drug delivery systems: A overview
Shirkhedkar et al. Herbal drugs for the treatment of ocular infections